ICON plc (ICLR) : Traders are bullish on ICON plc (ICLR) as it has outperformed the S&P 500 by a wide margin of 6.38% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.74%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.67% in the last 1 week, and is up 9.95% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.36% and the 50-Day Moving Average is 12.04%. ICON Public Limited Company is up 14.93% in the last 3-month period. Year-to-Date the stock performance stands at -0.04%.
ICON plc (NASDAQ:ICLR): On Fridays trading session , Opening price of the stock was $75.81 with an intraday high of $77.78. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $75.17. However, the stock managed to close at $77.67, a loss of 1.30% for the day. On the previous day, the stock had closed at $78.69. The total traded volume of the day was 889,539 shares.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.